Cohance Lifesciences Quarterly Results for Trading Insights
COHANCE • Latest quarterly financial performance to support trade journaling in Tickjournal
Latest Quarter Net Profit
₹66 Cr
QSept 2025
Cohance Lifesciences Quarterly Results Key Highlights
- Revenue of ₹571 Cr in Sept 2025 (-33.1% vs Mar 2025, -7.9% vs Sept 2024)
- Net Profit of ₹66 Cr in Sept 2025 (-43.6% vs Mar 2025, -52.2% vs Sept 2024)
- EBITDA of ₹137 Cr in Sept 2025 (-39.4% vs Mar 2025)
- Operating Margin of 22.0% in Sept 2025 (-3.0pp vs Mar 2025)
- Earnings Per Share of ₹1.94 in Sept 2025 (-38.6% vs Mar 2025)
Cohance Lifesciences Quarterly Results Analysis
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 571 | 853 | 564 | 620 | 270 | -33.1% | -7.9% |
| Net Profit (₹ Cr) | 66 | 117 | 46 | 138 | 53 | - | - |
| EBITDA (₹ Cr) | 137 | 226 | 118 | 222 | 90 | - | - |
| EPS (₹) | 1.94 | 3.16 | 1.28 | 3.63 | 2.10 | - | - |
| Operating Margin (%) | 22.0% | 25.0% | 19.0% | 34.0% | 29.0% | - | - |
Cohance Lifesciences Share Price Trend Around Quarterly Results
Visualize Cohance Lifesciences's 1-year price movement across quarterly results — ideal for logging trades in Cohance Lifesciences share price
chart using Tickjournal. All values in ₹.
Related Pages for Cohance Lifesciences
Additional stock information and data for COHANCE
Revenue Trend (₹ Cr)
Sept 2024
620
Jun 2025
564
Mar 2025
853
Sept 2025
571
Net Profit Trend (₹ Cr)
Sept 2024
138
Jun 2025
46
Mar 2025
117
Sept 2025
66
Operating Margin Trend (%)
Sept 2024
34.0%
Jun 2025
19.0%
Mar 2025
25.0%
Sept 2025
22.0%
Sector Competitors - Quarterly Performance Comparison
Comparing Cohance Lifesciences quarterly results with other companies in Healthcare sector
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹422,330.94 Cr | 1782.6 | 14,875 | 3,125 | +10.8% | - | 21.0% | 137.1 |
|
Divis Laboratories
Sept 2025 |
₹176,337.50 Cr | 6642.5 | 2,860 | 689 | +7.1% | - | 24.1% | 255.8 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹136,522.12 Cr | 4092.2 | 3,219 | 591 | +11.3% | - | 18.4% | 233.3 |
|
Cipla
Sept 2025 |
₹121,238.47 Cr | 1467.9 | 7,716 | 1,353 | +12.0% | - | 17.5% | 87.7 |
|
Dr Reddys Laborator…
Sept 2025 |
₹104,829.57 Cr | 1242.8 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.8 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores